BIA/ABPI Brexit Lead Network

The BIA and ABPI will hold a special Brexit Lead Network on the morning of 28th January to review the outcome of the Brexit deal for the life sciences sector and to begin to explore what comes next. We will be joined by Government experts on the detail of the deal, as well as issues such as supply and regulation.

As with previous meetings, this event is for members of ABPI and/or BIA and is intended for those leading Brexit activity within companies.


David Simmons

Director, Supply Resilience, DHSC

Office for Life Sciences at Department for Business, Energy and Industrial Strategy (BEIS)

Jonathan Mogford

Director of Policy


Matt Harpur

Deputy Director for Goods


Steve Bates

Chief Executive Officer


Steve Bates has been the CEO of the UK Bioindustry Association since 2012. He currently chairs the International Council of Biotech Associations and has been a Board member of Europabio since 2015. Steve is the visible face of the vibrant UK life sciences industry to government and media. He sits on the UK’s Life Sciences Council and Life Sciences Industrial Strategy Implementation Board. Steve has championed with government effective industrial incentives like the Biomedical Cataylst which have crowded-in private sector investment into UK SMES. He has forged links for the sector across the USA, Europe and in China. In his time at the BIA Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next generation talent and developing the skills needed for the sector to flourish. Before the BIA, Steve worked for Genzyme and as an advisor to the UK Government of Tony Blair. He was made OBE for services to innovation in 2017.

Richard Torbett

Chief Executive


Dr Richard Torbett joined ABPI in July 2015 and previously held the role of Executive Director of Economic, Health and Commercial Policy. In this role, Richard was responsible for pricing policy (including the Voluntary Scheme for Medicine Policy and Access -VPAS); Health Technology Assessment as well as the organisation's partnership activities with the NHS throughout the UK.

Richard has spent the last 14 years working in the pharmaceutical industry. Immediately prior to joining ABPI he was the Chief Economist at the European Federation of Pharmaceutical Industries and Associations (EFPIA) where he was responsible for strategy as well as economic analysis and EFPIA's relations with international economic institutions. He also spent six years at Pfizer Inc., most recently as Senior Director and Head of International Affairs.

Richard has degrees in economics from the University of Sussex and the University of Grenoble. He completed his PhD at the Science Policy Research Unit (SPRU), University of Sussex in 2001.


Registration is free for BIA and ABPI Members. 

Please click here to register